Seronegative rheumatoid arthritis affecting three or more distinct joint regions simultaneously, with negative rheumatoid factor lab results documented in the medical record.
Verified May 8, 2026 · 6 sources ↓
- Status
- Billable
- Chapter
- 13
- Related CPT
- 9
- Region
- Multi-region
Documentation tips
What should appear in the chart to support M06.09.
Source · Editorial brief grounded in 6 cited references ↓
- Explicitly document rheumatoid factor status as negative (seronegative) — 'RF negative' or 'seronegative RA' — to justify M06.x over M05.x or M06.9.
- List every affected joint region by name (e.g., bilateral wrists, bilateral MCPs, right knee) to substantiate the 'multiple sites' specificity and avoid a downcode to M06.9.
- Record anti-CCP (anti-cyclic citrullinated peptide) results separately; a negative RF with positive anti-CCP is still coded under M06 for RF status, but the anti-CCP result is clinically significant for prognosis and biomarker testing justification.
- Document disease activity level (remission, low, moderate, high) and any current DMARD or biologic therapy — required for medical necessity when billing infusion or molecular biomarker CPT codes alongside this diagnosis.
- If imaging was performed, record joint-specific findings (erosions, synovitis, joint space narrowing) per anatomical site to corroborate multi-site involvement in the record.
Related CPT procedures
Procedure codes commonly billed with M06.09. Linking the right diagnosis to the right procedure is what establishes medical necessity.
Source · CMS LCDs · AAOS specialty guidance · claims-pattern analysis
Common coding pitfalls
The recurring mistakes coders make with M06.09 and adjacent codes.
Source · Editorial brief grounded in CDC ICD-10-CM tabular guidance, AAOS coding references, and cited references ↓
- Using M06.09 when RF status is not documented: if the chart says only 'RA, multiple joints' without noting seronegative status, the correct code is M06.9, not M06.09.
- Defaulting to M06.09 when individual site-specific codes exist and the patient's involvement is limited to one or two joint pairs — assign the site-specific M06.0xx codes instead.
- Confusing M06.09 (seronegative RA, multiple sites) with M05.79 (seropositive RA, multiple sites) — verify RF lab documentation before choosing the M05 vs. M06 parent category.
- Omitting laterality documentation for individual joints: while M06.09 itself doesn't carry a laterality character, the underlying clinical record must support multi-site involvement, and vague documentation invites audit scrutiny.
- Pairing M06.09 with M06.9 on the same claim — these are mutually exclusive; M06.09 is the more specific code and should be used alone when seronegative multi-site RA is confirmed.
Clinical context
Source · Editorial summary grounded in 6 cited references ↓
M06.09 applies to patients diagnosed with rheumatoid arthritis whose rheumatoid factor (RF) serology is negative — commonly called seronegative RA — and whose disease involves multiple joint sites. The 'multiple sites' designation means the clinician has documented active RA in three or more anatomical regions (e.g., bilateral wrists, bilateral MCPs, and knees) in a single encounter. If the RF status is not documented, use M06.9 (rheumatoid arthritis, unspecified). If RF is documented as positive, the correct parent category is M05, not M06.
M06.09 sits under parent code M06.0 (rheumatoid arthritis without rheumatoid factor), which includes site-specific child codes for shoulder (M06.01x), elbow (M06.02x), wrist (M06.03x), hand (M06.04x), hip (M06.05x), knee (M06.06x), ankle/foot (M06.07x), and vertebrae (M06.08). Use M06.09 only when the clinical record explicitly identifies involvement at multiple sites — not as a default when individual site codes feel cumbersome. If the patient has seronegative RA limited to a single bilateral pair of joints (e.g., both knees only), assign the bilateral site-specific codes instead.
This code is recognized by CMS as supporting medical necessity for molecular biomarker testing used to guide targeted therapy selection in RA (CMS LCD A59536, A56541). When the patient is being evaluated for biologic or targeted synthetic DMARD therapy, M06.09 may be paired with appropriate procedure codes for infusion, injection, or lab services. MS-DRG v43.0 groups M06.09 into DRGs 545–547 (Connective tissue disorders with/without MCC/CC).
Sibling codes
Other billable codes under M06.0 (laterality / anatomic variants).
Frequently asked questions
Source · Generated from the editorial pipeline, verified against 6 cited references ↓
01What is the difference between M06.09 and M06.9?
02Can I use M06.09 when anti-CCP is positive but RF is negative?
03When should I use site-specific M06.0xx codes instead of M06.09?
04Does M06.09 support medical necessity for biologic infusion therapy?
05What MS-DRGs does M06.09 map to?
06Should I code M06.09 alongside individual joint codes for the same patient?
Sources & references
Editorial content was developed using the following public sources. Last verified May 8, 2026.
- 01CDC ICD-10-CM Tabular List 2026 — code M06.09
- 02icd10data.comhttps://www.icd10data.com/ICD10CM/Codes/M00-M99/M05-M14/M06-/M06.09
- 03cms.govhttps://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=59536&ver=7
- 04cms.govhttps://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=56541&ver=40
- 05cdc.govhttps://www.cdc.gov/nchs/icd/icd-10-cm/index.html
- 06aapc.comhttps://www.aapc.com/codes/icd-10-codes/M06.09
Mira AI Scribe
Mira captures RF serology status (negative), each named joint region involved, disease activity level, current DMARD or biologic therapy, and any imaging findings per site. This prevents a downcode to unspecified M06.9 and closes the documentation gap that triggers medical necessity denials for biologic therapy infusions and molecular biomarker testing under CMS LCD A59536.
See how Mira captures M06.09 documentation